IGRT in Prostate Cancer: Focus on BAT Ultrasound

Joshua S. Silverman; Eric M. Horwitz

doi:10.3109/9781420060799-13

IGRT in Prostate Cancer: Focus on BAT Ultrasound

Joshua S. Silverman, Eric M. Horwitz

Fox Chase Cancer Center

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

There are several rationales for the use of daily image-guided radiation therapy (IGRT) in the management of prostate cancer. The ability to consistently and reprodu-cibly deliver the prescribed dose of radiation to the target is the most obvious reason. Another reason is the ability to safely escalate radiation dose. The first reports illustrating this dose response appeared in 1995, and since that time, multiple single-institution prospective, retrospective, and phase III randomized prospective trials have confirmed this phenomenon in prostate cancer. These studies have consistently demonstrated an improvement in biochemical control as an increasing dose of radiation is delivered to the prostate (1,3,4). Finally, IGRT allows for the limiting of dose to adjacent critical structures and the reduction of early and late complications. Dose-volume effects have been described in the literature for both the bladder and rectum (5,6).

Original language	English
Title of host publication	Image-Guided Radiation Therapy of Prostate Cancer
Publisher	CRC Press
Pages	103-111
Number of pages	9
ISBN (Electronic)	9781420060799
ISBN (Print)	9781420060782
DOIs	https://doi.org/10.3109/9781420060799-13
State	Published - Jan 1 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/9781420060799-13

Cite this

@inbook{16ccc54a05ea4e0382d0c9137648eea7,

title = "IGRT in Prostate Cancer: Focus on BAT Ultrasound",

abstract = "There are several rationales for the use of daily image-guided radiation therapy (IGRT) in the management of prostate cancer. The ability to consistently and reprodu-cibly deliver the prescribed dose of radiation to the target is the most obvious reason. Another reason is the ability to safely escalate radiation dose. The first reports illustrating this dose response appeared in 1995, and since that time, multiple single-institution prospective, retrospective, and phase III randomized prospective trials have confirmed this phenomenon in prostate cancer. These studies have consistently demonstrated an improvement in biochemical control as an increasing dose of radiation is delivered to the prostate (1,3,4). Finally, IGRT allows for the limiting of dose to adjacent critical structures and the reduction of early and late complications. Dose-volume effects have been described in the literature for both the bladder and rectum (5,6).",

author = "Silverman, {Joshua S.} and Horwitz, {Eric M.}",

note = "Publisher Copyright: {\textcopyright} 2008 by Informa Healthcare USA, Inc.",

year = "2008",

month = jan,

day = "1",

doi = "10.3109/9781420060799-13",

language = "English",

isbn = "9781420060782",

pages = "103--111",

booktitle = "Image-Guided Radiation Therapy of Prostate Cancer",

publisher = "CRC Press",

}

TY - CHAP

T1 - IGRT in Prostate Cancer

T2 - Focus on BAT Ultrasound

AU - Silverman, Joshua S.

AU - Horwitz, Eric M.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - There are several rationales for the use of daily image-guided radiation therapy (IGRT) in the management of prostate cancer. The ability to consistently and reprodu-cibly deliver the prescribed dose of radiation to the target is the most obvious reason. Another reason is the ability to safely escalate radiation dose. The first reports illustrating this dose response appeared in 1995, and since that time, multiple single-institution prospective, retrospective, and phase III randomized prospective trials have confirmed this phenomenon in prostate cancer. These studies have consistently demonstrated an improvement in biochemical control as an increasing dose of radiation is delivered to the prostate (1,3,4). Finally, IGRT allows for the limiting of dose to adjacent critical structures and the reduction of early and late complications. Dose-volume effects have been described in the literature for both the bladder and rectum (5,6).

AB - There are several rationales for the use of daily image-guided radiation therapy (IGRT) in the management of prostate cancer. The ability to consistently and reprodu-cibly deliver the prescribed dose of radiation to the target is the most obvious reason. Another reason is the ability to safely escalate radiation dose. The first reports illustrating this dose response appeared in 1995, and since that time, multiple single-institution prospective, retrospective, and phase III randomized prospective trials have confirmed this phenomenon in prostate cancer. These studies have consistently demonstrated an improvement in biochemical control as an increasing dose of radiation is delivered to the prostate (1,3,4). Finally, IGRT allows for the limiting of dose to adjacent critical structures and the reduction of early and late complications. Dose-volume effects have been described in the literature for both the bladder and rectum (5,6).

UR - http://www.scopus.com/inward/record.url?scp=85179281406&partnerID=8YFLogxK

U2 - 10.3109/9781420060799-13

DO - 10.3109/9781420060799-13

M3 - Chapter

AN - SCOPUS:85179281406

SN - 9781420060782

SP - 103

EP - 111

BT - Image-Guided Radiation Therapy of Prostate Cancer

PB - CRC Press

ER -

IGRT in Prostate Cancer: Focus on BAT Ultrasound

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this